An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day−1 in adult patients with refractory epilepsy
Open Access
- 1 April 2003
- Vol. 12 (3) , 141-149
- https://doi.org/10.1016/s1059-1311(02)00292-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?Epilepsia, 2001
- Levetiracetam does not modulate neuronal voltage-gated Na+and T-type Ca2+currentsSeizure, 2001
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyPublished by Elsevier ,1998
- The new generation of antiepileptic drugs: advantages and disadvantagesBritish Journal of Clinical Pharmacology, 1996
- The Clinical Pharmacokinetics of the Newer Antiepileptic DrugsClinical Pharmacokinetics, 1996
- The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEuropean Journal of Pharmacology, 1995
- Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsyEpilepsy Research, 1995
- Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and ratsEuropean Journal of Pharmacology, 1993
- ucb L059, a novel anti-convulsant drug: pharmacological profile in animaisEuropean Journal of Pharmacology, 1992